Neumora Therapeutics (NMRA) Capital Expenditures (2022 - 2023)
Neumora Therapeutics' quarterly Capital Expenditures came in at -$29000.0 in Q4 2023, down 105.98% year-on-year from $485000.0 in Q4 2022, and down 178.38% quarter-over-quarter from $37000.0 in Q3 2023.
Neumora Therapeutics has reported Capital Expenditures for 2 years, with the latest figure at -$29000.0 in Q4 2023.
- For the quarter ending Q4 2023, Capital Expenditures fell 105.98% year-over-year to -$29000.0; the trailing twelve-month figure through Dec 2023 stood at $44000.0 (changed N/A YoY), and the FY2023 full-year result was $44000.0, down 91.29% from the prior year.
- Capital Expenditures for Q4 2023 stood at -$29000.0, down from $37000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $485000.0 in Q4 2022, with the low at -$29000.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -29,000.00 |
| Dec 31, 2023 | -29,000.00 |
| Sep 30, 2023 | 37,000.00 |
| Sep 30, 2023 | 37,000.00 |
| Mar 31, 2023 | 36,000.00 |
| Mar 31, 2023 | 36,000.00 |
| Dec 31, 2022 | 485,000.00 |
| Dec 31, 2022 | 485,000.00 |